A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

20241,508 citationsJournal Articlegreen Open Access

Authors

Stephen A. Harrison · Inserm

Pierre Bédossa · Inserm

Cynthia D. Guy · Inserm

Jörn M. Schattenberg · Inserm

Rohit Loomba · Inserm

Rebecca Taub · Inserm

Dominic Labriola · Inserm

Abstract

Both the 80-mg dose and the 100-mg dose of resmetirom were superior to placebo with respect to NASH resolution and improvement in liver fibrosis by at least one stage. (Funded by Madrigal Pharmaceuticals; MAESTRO-NASH ClinicalTrials.gov number, NCT03900429.).

Topics & Keywords

Liver Disease Diagnosis and Treatment Liver Diseases and Immunity Drug Transport and Resistance Mechanisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 390, Issue 6, pp. 497-509

DOI: 10.1056/nejmoa2309000

Field-Weighted Citation Impact: 576.66